Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Plus Carboplatin in Refractory Prostate Cancer
NCT00134706Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2004
- Primary completion
- Apr 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Started Jan 2004; status: completed.
02
Drugs
carboplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00134706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134706.